“This is a possible scenario, however, once the

“This is a possible scenario, however, once the drug is approved for one indication the dam will fall down and extended label or, better, off-label will be unstoppable.”

“Unstoppable” is a very big assumption. Why? Because 99.9% of doctors, physician assistants, and nurse practitioners don’t know what leronlimab is. Let’s says it gets approved for COVID. Many, many more will know leronlimab at that point but I’m positive that the majority won’t consider prescribing it off-label. Why? Because leronlimab hasn’t been officially tested in all of the indications the MOA may apply to and most providers won’t have the ability to prescribe it.

“Please remember, Leronlimab is safe. Doctor will start prescribing, data will come, sales will increase ...”

Safety is important but you need to consider this: insurance companies control which drugs are available to patients in their systems. More expensive drugs, especially drugs for off-label indications, aren’t widely approved and often times require a special drug request with justification. Just becuase Leronlimab is approved for COVID19 doesn’t mean an insurance company is going to approve a payment of $1-3K for a patient to try the drug for their autoimmune disorder based on the MOA.. Now, this might happen on a small scale I’m specialty clinics and eventually spread once small studies emerge, but that could take years.